Analyst Update: Match, Teva Pharma, and Michael Kors

Analysts are weighing in today on Internet dating concern Match Group Inc (NASDAQ:MTCH), drug company Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and luxury retailer Michael Kors Holdings Ltd (NYSE:KORS). Here's a quick roundup of today's brokerage notes on MTCH, TEVA, and KORS.

• MTCH was last seen trading at $14.87, a loss of 2.2%, after finishing Friday at a 27% premium to its $12.00 initial public offering (IPO) price on Thursday. Two brokerage firms initiated coverage on the shiny new stock today, with BTIG doling out a bearish "sell" rating and $11 price target, while Axiom gave Match Group Inc a bullish nod, with a "buy" rating and $18 price target. However, eager speculators will have to keep waiting before options can be traded on Match Group Inc.

• TEVA received a rating boost to "buy" from "neutral" at Goldman Sachs, helping the shares climb 1.2% to $62.41 so far today. Teva Pharmaceutical Industries Ltd may be enjoying some extra attention thanks to major M&A news from sector peer Pfizer Inc. (NYSE: PFE). TEVA reported quarterly earnings above estimates last month, and has gained favor with analysts and options traders alike. Of the 17 firms following TEVA, 12 give it a "buy" rating or better. Even more impressive, the stock's 50-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 6.91 is higher than 93% of readings from the last 52 weeks -- meaning options buyers have rarely purchased calls over puts at a faster clip.

• It's a good day on the charts so far for KORS, last seen up 1.7% to trade at $41.82, despite a price-target cut to $45 from $46 at Goldman Sachs. Michael Kors Holdings Ltd has been trending mostly sideways for months, ever since staging a late-May bear gap after earnings. The luxury brand beat quarterly earnings expectations earlier this month, but has yet to stage a convincing breakout above resistance at its 20-week moving average. As it stands, analysts are rather uncertain concerning the future of this stock, with 15 of the 19 brokerages following KORS maintaining a tepid "hold" rating, and just a few outliers on either side of the fence.